Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cutaneous melanomas exhibiting unusual biologic behavior.

H M Shaw1, J K Rivers, S W McCarthy

  • 1Sydney Melanoma Unit, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

World Journal of Surgery
|March 1, 1992
PubMed
Summary

Malignant melanoma thickness can be unpredictable. Certain thin melanomas with ulceration or high mitotic activity may recur, while some thick melanomas have better prognoses, challenging standard follow-up guidelines.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Subungual Melanoma of the Hand.

Annals of surgical oncology·2018
Same author

Non-Invasive Gene Expression Testing to Rule Out Melanoma.

Skin therapy letter·2018
Same author

The correlation between clinical and histological clearance of actinic keratoses.

The British journal of dermatology·2017
Same author

Actikerall™ (5-Fluorouracil 0.5% and Salicylic Acid 10%) Topical Solution for Patient-directed Treatment of Actinic Keratoses.

Skin therapy letter·2016
Same author

A recurrent germline BAP1 mutation and extension of the BAP1 tumor predisposition spectrum to include basal cell carcinoma.

Clinical genetics·2014
Same author

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

European journal of cancer (Oxford, England : 1990)·2014

Area of Science:

  • Dermatology
  • Oncology
  • Pathology

Background:

  • Malignant melanoma thickness is a primary prognostic factor, but rare cases defy prediction.
  • Unusual melanomas, including thin lesions with metastasis and thick lesions with favorable outcomes, necessitate further study.
  • Long-term follow-up protocols may not suit all melanoma patients.

Purpose of the Study:

  • To investigate the characteristics and prognosis of unusual malignant melanomas.
  • To identify predictors of recurrence in thin melanomas and understand factors in thick melanomas.
  • To evaluate the appropriateness of current melanoma follow-up guidelines.

Main Methods:

  • Analysis of a large database of over 9,500 melanoma patients treated over 41 years.
  • Examination of histological features (ulceration, mitotic activity, dermal invasion, regression) in relation to disease course.

Related Experiment Videos

  • Comparison of thin melanoma characteristics in Stage I (localized) versus Stage II (regional metastasis) patients.

    • Main Results:

    • In Stage I thin melanomas, ulceration, high mitotic activity, and reticular dermis penetration predicted recurrence; regression was not a risk factor.
    • Stage II thin melanomas with lymph node metastasis showed moderate to severe regression, absent ulceration/mitoses, and limited dermal invasion.
    • No criteria identified low-risk Stage I/II thick melanomas or Stage I patients needing >10-year follow-up.

    Conclusions:

    • Standard melanoma prognostic indicators may not apply to all cases.
    • Histological features differ significantly between thin melanomas with and without lymph node metastasis.
    • Current follow-up guidelines may require revision for a subset of melanoma patients.